Homepage - Mersana

Mersana Therapeutics employs its biodegradable polymer platform (Fleximer^®) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas.

June 23, 2010 Mersana Initiates Phase 1 Clinical Trial for XMT-1107 in Oncology. >> more April 20, 2010 Mersana Therapeutics Presents Data Demonstrating XMT-1001 Substantially Accumulates in Tumor and Results in Significantly Prolonged Drug Exposure. >> more		Share Mersana Therapeutics employs its biodegradable polymer platform (Fleximer^®) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas.